A phase III trial of remetinostat for the treatment of early-stage cutaneous T-cell lymphoma
Phase of Trial: Phase III
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Remetinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Medivir AB
- 18 Jun 2018 According to a Medivir AB media release, the company decided to continue the discussions with the US Food and Drug Administration (FDA) to agree on the design and start of the study will not be possible earlier than 2019.
- 14 Feb 2018 According to a Medivir AB media release, discussions with regulatory authorities on the design of this study are underway.
- 07 Apr 2017 According to a Medivir AB media release, based on the data from Phase II trial (see profile 243325) company is planning to initiate discussions with regulatory authorities with the aim of initiating this trial later in 2017.